3.2.2020
Гитлер строил крематории рядом с крупными университетами,чтобы не отходя от кассы проводить исследования.Современным хитлерам весть мир-концлагерь без ковычек.И каждый может стать подопытной крысой.
One of the best ways to save humanity from a global pandemic in the future is by developing infectious disease vaccines now. But research has been sluggish, partly because no one knows how much producing such vaccines would cost.
That changed last week(октябрь 2018) when researchers from the Coalition for Epidemic Preparedness Innovations (CEPI) published a study in Lancet estimating the cost of developing vaccines for diseases that have the potential to escalate into global humanitarian crises.
Preventing pandemics is extremely important work: In the next two decades, experts believe, there is a reasonable probability of a pandemic that kills more than 30 million people worldwide. Compare that to the 2014 Ebola outbreak, which killed more than 11,000 people across three countries — partially because we didn’t have a vaccine at the time.
But vaccines are expensive and hard to get off the ground. According to the Lancet, “In general, vaccine development from discovery to licensure can cost billions of dollars, can take over 10 years to complete, and has an average 94% chance of failure.” It’s a risky investment not many people want to make — until, of course, there’s a deadly outbreak like in 2014. By then, it’s often already too late.
The group - made up of seven British nationals and four family members - will join 83 people already under observation after being flown back from Wuhan on Friday.
Meanwhile, Health Secretary Matt Hancock has announced that ;20m of UK government investment would be used to develop a vaccine to combat the deadly global disease.
The investment will go to the Coalition for Epidemic Preparedness Innovations (CEPI), a global body that is aiming to fast-track a coronavirus vaccine within six to eight months.
CEPI chief executive Dr Richard Hatchett said: "This is an extremely ambitious timeline - indeed, it would be unprecedented in the field of vaccine development.
"It is important to remember that even if we are successful - and there can be no guarantee - there will be further challenges to navigate before we can make vaccines more broadly available."
It comes after a UK-wide campaign was launched offering the public advice on how to stop the spread of the deadly virus following Britain's first two confirmed cases.
The pair - who fell ill while staying at a hotel in York - are members of the same family, and one of them is a student at the University of York.
The two patients are being treated at a specialist hospital unit in Newcastle and health authorities are urgently trying to trace anyone who has come into contact with them.
Of the 266 tests so far carried out in the UK, two have been positive.
The 11 UK citizens arrived back from China on Sunday on board a Maltese plane arranged by France. Sky News understands the group of Britons includes children.
Foreign Secretary Dominic Raab told Sky's Sophy Ridge On Sunday: "They will go to the Arrowe Park facility and all of the protections, the support during the 14-day period will be put in place.
"So they will be treated very well, and of course the reason we need to do that is on the one hand we want to get the UK nationals that want to leave China out, on the other hand we need to make sure we control and prevent the spread of the coronavirus because of the implications that that would have."
Yvonne Griffiths, a British lecturer who is among the 83 people already at the facility, spoke to Sky News from her room in quarantine, saying they are being treated well but are unsure whether their isolation will be extended because of the arrival of the new group .
As of April 2018, CEPI had invested $37.5 million in Austria-based Themis Bioscience[6] and $56 million in US-based Inovio Pharmaceuticals, Inc. to develop vaccine candidates against Lassa fever and MERS.
CEPI published a study in the Lancet in 2018 which estimated the costs of developing vaccines for diseases that could escalate into global humanitarian crises. The study focused on 11 diseases which cause relatively few deaths at present and primarily strike the poor. The authors estimated that it would cost between $2.8 billion and $3.7 billion to develop at least one vaccine for each of the diseases. This should be set against the potential cost of an outbreak. The 2003 SARS outbreak in East Asia cost $54 billion.